BioSpace News Archive

Calibre Scientific is pleased to announce the acquisition of Serviquimia, a high-quality distributor of consumables, chemicals, lab equipment, and lab furniture, headquartered in Tarragona, Spain.

The Pennsylvania and Maryland Departments of Health have granted Immunovia, Inc., the US subsidiary of Immunovia AB, Clinical Laboratory permits, allowing physicians in Pennsylvania and Maryland to order the IMMray™ PanCan-d test for their patients.

Modra Pharmaceuticals announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer at the upcoming ASCO General Annual Meeting held from June 3 – 7, 2022 virtually and in-person in Chicago, IL, USA.

Endotronix, Inc. announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System in New York Heart Association class III heart failure patients.

Axon Therapies, a private company focused on addressing a root cause of heart failure, announced positive early results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF.

Ocugen, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™.

ImmunoGen, Inc. announced that the US Food and Drug Administration has accepted and filed the Biologics License Application for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.

Elicio Therapeutics today announced the publication of findings from a preclinical study showing enhanced anti-tumor function and eradication of solid tumors by combining its Amphiphile (AMP) platform vaccine, carrying cognate peptide and adjuvant cargos, with T cell receptor T cell therapies (TCR-Ts).

Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago, IL from June 3 to 7, 2022.

Starton Therapeutics Inc., a clinical stage biotechnology company announced today that the Independent Data Monitoring Committee reviewed the totality of the safety data from the first two cohorts and recommended advancement to the third- and final dose escalation, where subjects will receive the highest infusion strength of STAR-LLD.